Whilst, blockade of NFκB resulting in a corresponding decline in angiogenic VEGF has not been well documented in endothelial cell models, related studies with breast cancer cell lines such as those in MDA-MB-231 have displayed successful VEGF suppression with an NFκB inhibitor [53]. This evidence concerns the gene VEGFA and breast carcinoma.